Tyrosine Kinase Inhibitor

CHICAGO — Cabozantinib plus atezolizumab showed encouraging clinical activity in patients with inoperable locally advanced or metastatic urothelial carcinoma, according to data from the COSMIC-021 study.

CHICAGO — Asciminib continued to confer superior efficacy and better safety and tolerability than bosutinib among patients with chronic-phase chronic myeloid leukemia, according to study results presented during ASCO Annual Meeting.

BOSTON – In this video interview, Christy S. Harris, PharmD, BCOP, FHOPA, talked about poster sessions presented at Hematology/Oncology Pharmacy Association Annual Meeting.

BOSTON – Christy S. Harris, PharmD, BCOP, FHOPA, discussed a presentation on the role of immunotherapy in upper gastrointestinal cancer and how it’s “trying to move the needle forward” in care.

In a recent American Heart Association scientific statement, a committee provided an overview of drug-to-drug interactions between cancer drugs and commonly used CV medications.

As new therapeutic options for mantle cell lymphoma emerge, physicians are learning where they best fit into the treatment armamentarium.

In the last two decades, the approval of multiple tyrosine kinase inhibitors for chronic myeloid leukemia has vastly improved the treatment landscape for patients.

Targeted therapies in HER2-positive breast cancer are integral to the success of treatment outcomes in this patient population.

In this video, Alexander Edward Perl, MD, MS, spoke with Healio about a study assessing the outcome of patients with acute myeloid leukemia who received gilterintib with prior midostaurin or sorafenib therapy.

The FDA approved mobocertinib for treatment of certain patients with non-small cell lung cancer.